Biofactories Applied to Future Antivenom Production

Posted by
  Image Credit: By Ssiltane - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=52242648 Biofactories Applied to Future Antivenom Production Abstract Background: Accidents caused by the  Loxosceles laeta  spider constitute a health problem in South America. Envenomation can lead to severe systemic manifestations, eventually compromising the patient’s life. Most regional health authorities consider antivenom administration the basis of effective treatment in the most serious cases. The availability of spider venom is the primary bottleneck for antivenom production. Herein, we present a novel biotechnological approach, based on the expression of recombinant versions of the most relevant toxin in loxoscelism, sphingomyelinase D (SphD), in insect larvae ( Spodoptera frugiperda ).  Methods: We produced two versions of SphD: one conserving its biological activities (wtSphD) and a second alternative that was designed to be genetically detoxified (dSphD...

First Clinical Report on Efficacy of Alternative European Viper Antivenoms in Treatment of Vipera ammodytes Envenomation in Croatia

Posted by

 

Image Credit: By Holger Krisp - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=15435685

First Clinical Report on Efficacy of Alternative European Viper Antivenoms in Treatment of Vipera ammodytes Envenomation in Croatia

Abstract

In Croatia, the European Viper Venom Antiserum®, produced by the Institute of Immunology Zagreb, was the only antiserum used to treat Vipera ammodytes envenomation. When production of the Zagreb antivenom ceased, three other antivenoms, Viperfav®, BulBio®, and Viekvin®, replaced it in clinical practice at the Department of Infectious Diseases, University Hospital Split. This study includes 34 patients envenomed by Vipera ammodytes during the period between 2020 and 2025: 24 (71%) suffered grade 2a envenomation, nine (26%) grade 2b, and one grade 3 (severe envenomation). None were admitted to the Intensive Care Unit. All patients received antivenom: 16 received Viperfav®, 17 BulBio®, and one Viekvin®. All grade 2a patients were treated with a single dose of antivenom. Among grade 2b patients, four received one dose and two received two doses of Viperfav®, while one received one dose and two received two doses of BulBio®. The grade 3 patient received two doses of BulBio®. In all cases, treatment was successful and patients were discharged from hospital after an average of 3.97 days. Patients with pronounced neurotoxic signs did not require treatment with multiple doses of antivenom. All antivenoms proved effective. No adverse reactions or fatalities were observed.

Šimunković, M. Č., Leonardi, A., Križaj, I., & Karabuva, S. (2026). First Clinical Report on Efficacy of Alternative European Viper Antivenoms in Treatment of Vipera ammodytes Envenomation in Croatia. Toxins, 18(4). https://doi.org/10.3390/toxins18040178